Low Microsomal Epoxide Hydrolase Expression is Associated with Bladder Carcinogenesis and Recurrence

Zhang, Zhe; Yu, Xiuyue; Zhang, Guojun; Guo, Kun-Feng; Kong, Chuize

doi:10.7314/apjcp.2012.13.2.521

Cited by 4 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These polymorphisms have been shown to be connected with prostate cancer, colorectal cancer, and bladder cancer. [3][4][5] In different studies it has been suggested that lung cancer and breast cancer are associated with risk. However, the results are uncertain.…”

Section: Introductionmentioning

confidence: 99%

The connection between microsomal epoxide hydrolase enzyme and cancer risk

Okat¹

2018

IPMRJ

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

The connection between microsomal epoxide hydrolase enzyme and cancer risk

Okat¹

2018

IPMRJ

View full text Add to dashboard Cite

show abstract

“…These polymorphisms may be associated with prostate cancer, colorectal cancer, and bladder cancer (Mittal and Srivastava, 2007;Liu et al, 2012;Zhang et al, 2012). Previous studies have suggested that the EPHX1 Tyr113His polymorphisms associated with the risk for lung cancer and breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Quantitative assessment of the effects of the EPHX1 Tyr113His polymorphism on lung and breast cancer

et al. 2014

View full text Add to dashboard Cite

ABSTRACT. The association between the microsomal epoxide hydrolase 1 gene (EPHX1) Tyr113His polymorphism and lung cancer and breast cancer risk has been reported in many recent studies, but there is no consensus among the results. Thus, we examined the association between the EPHX1 Tyr113His polymorphism and lung cancer through a meta-analysis. A comprehensive literature search was performed using the Pubmed and Embase databases. Odds ratios with 95% confidence intervals were used to assess the strength of associations. Our meta-analysis suggested that the Tyr113His polymorphism was associated with lung cancer risk in Asians under 3 genetic models, including a C vs T, CC vs TT, and recessive model. However, the risk was decreased in Caucasians under the genetic models, including a C vs T, CC vs TT, or CT vs TT, dominant, and recessive model. In contrast, there was no association with breast cancer risk for any of the genetic models. Our meta-analysis suggested that the EPHX1 Tyr113His polymorphism may be a risk factor for lung cancer in Asians, whereas it may be a decreased risk factor among Caucasians. However, this polymorphism was not found to be associated with breast cancer.

show abstract

Extrahepatic metabolism at the body's internal–external interfaces

Gundert‐Remy

Bernauer

Blömeke

et al. 2014

Drug Metabolism Reviews

View full text Add to dashboard Cite

In general, xenobiotic metabolizing enzymes (XMEs) are expressed in lower levels in the extrahepatic tissues than in the liver, making the former less relevant for the clearance of xenobiotics. Local metabolism, however, may lead to tissue-specific adverse responses, e.g. organ toxicities, allergies or cancer. This review summarizes the knowledge on the expression of phase I and phase II XMEs and transporters in extrahepatic tissues at the body's internal-external interfaces. In the lung, CYPs of families 1, 2, 3 and 4 and epoxide hydrolases are important phase I enzymes, while conjugation is less relevant. In skin, phase I-related enzymatic reactions are considered less relevant. Predominant skin XMEs are phase II enzymes, whereby glucuronosyltransferases (UGT) 1, glutathione-S-transferase (GST) and N-acetyltransferase (NAT) 1 are important for detoxification. The intestinal epithelium expresses many transporters and phase I XME with high levels of CYP3A4 and CYP3A5 and phase II metabolism is mainly related to UGT, NAT and Sulfotransferases (SULT). In the kidney, conjugation reactions and transporters play a major role for excretion processes. In the bladder, CYPs are relevant and among the phase II enzymes, NAT1 is involved in the activation of bladder carcinogens. Expression of XMEs is regulated by several mechanisms (nuclear receptors, epigenetic mechanisms, microRNAs). However, the understanding why XMEs are differently expressed in the various tissues is fragmentary. In contrast to the liver - where for most XMEs lower expression is demonstrated in early life - the XME ontogeny in the extrahepatic tissues remains to be investigated.

show abstract

Low Microsomal Epoxide Hydrolase Expression is Associated with Bladder Carcinogenesis and Recurrence

Cited by 4 publications

References 25 publications

The connection between microsomal epoxide hydrolase enzyme and cancer risk

The connection between microsomal epoxide hydrolase enzyme and cancer risk

Quantitative assessment of the effects of the EPHX1 Tyr113His polymorphism on lung and breast cancer

Extrahepatic metabolism at the body's internal–external interfaces

Contact Info

Product

Resources

About